Predictive value of neutrophil-lymphocyte ratio for prognosis in patients with advanced hepatocellular carcinoma treated with programmed cell death 1 inhibitors

doi:10.3748/wjg.v32.i18.118416

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 18

This Article

(22)

(32)

(1)

(0)

(37)

(2)

(778)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 14, 2026; 32(18): 118416
Published online May 14, 2026. doi: 10.3748/wjg.v32.i18.118416

Table 7 Comparison of efficacy between patients with low neutrophil-to-lymphocyte ratio and high neutrophil-to-lymphocyte ratio, n (%)

Variable	Low NLR group (n = 129)	High NLR group (n = 105)	χ²	P value
CR	21 (16.28)	8 (7.62)
PR	25 (19.38)	9 (8.57)
SD	46 (35.66)	43 (40.95)
PD	37 (28.68)	45 (42.86)
ORR	46 (35.66)	17 (16.19)	10.386	0.001
DCR	92 (71.32)	60 (57.14)	5.110	0.024

NLR: Neutrophil-to-lymphocyte ratio; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

Full Size Table

Citation: Guo R, Gao M. Predictive value of neutrophil-lymphocyte ratio for prognosis in patients with advanced hepatocellular carcinoma treated with programmed cell death 1 inhibitors. World J Gastroenterol 2026; 32(18): 118416
URL: https://www.wjgnet.com/1007-9327/full/v32/i18/118416.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i18.118416